[Prescription of high-cost medicines in French Hospitals: Regulation and procedures of reimbursement].
Fiche publication
Date publication
avril 2016
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VIGNOT Stéphane
Tous les auteurs :
Wilkowsky C, Lenain A, Benbekhaled K, Le Gall MJ, Vignot S
Lien Pubmed
Résumé
The high cost of several drugs or medical devices involves specific reimbursement procedures in French hospitals. Specific prescription rules have been developed and a regular survey by regional health authorities is performed. These particular funding procedures allow patients to access to innovative drugs. Some questions have recently been raised in France about the list of cancer drugs that could be concerned by an additional funding by health insurance. In this setting, this article proposes to summarize the current modalities of reimbursement of high-cost medicines in French Hospitals to enlighten the current debate.
Mots clés
Cancer, Contrat de bon usage, Groupe homogène de séjour, Health insurance, Reimbursement of high-cost medicines, Remboursement des molécules onéreuses
Référence
Bull Cancer. 2016 04;103(4):353-60